Magic Touch sirolimus-coated balloon: animal and clinical evidence of a coronary sirolimus drug-coated balloon.
Bernardo CorteseSara MalakoutiJacinthe KhaterAmit MunjalPublished in: Future cardiology (2024)
The Magic Touch sirolimus-coated balloon (SCB) was recently introduced in Europe and features robust clinical technology different from other devices on the market. This device is able to deliver a sufficient sirolimus dose to the target segment to reduce neointimal proliferation with very little exposure downstream and no apparent adverse effects at sustained high drug concentrations. The SCB represents a promising novelty within the drug-coated balloon arena due to its mid-term efficacy and safety in the treatment of coronary artery disease, especially in de novo and small-vessel coronary lesions. The purpose of this article is to provide an up-to-date overview of the currently available animal and clinical trial results, as well as to highlight ongoing trials on the Magic Touch SCB.
Keyphrases
- coronary artery disease
- clinical trial
- coronary artery
- percutaneous coronary intervention
- coronary artery bypass grafting
- adverse drug
- drug induced
- heart failure
- type diabetes
- emergency department
- open label
- computed tomography
- smooth muscle
- magnetic resonance imaging
- study protocol
- double blind
- acute coronary syndrome
- phase ii
- left ventricular
- combination therapy
- smoking cessation
- transcatheter aortic valve replacement
- contrast enhanced